Electra Therapeutics, Inc. Common stock - Asset Resilience Ratio
Electra Therapeutics, Inc. Common stock (ETRA) has an Asset Resilience Ratio of 29.31% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Electra Therapeutics, Inc. Common stock carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2024–2025)
This chart shows how Electra Therapeutics, Inc. Common stock's Asset Resilience Ratio has changed over time. See financial flexibility index of Electra Therapeutics, Inc. Common stock to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Electra Therapeutics, Inc. Common stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Electra Therapeutics, Inc. Common stock balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $31.22 Million | 29.31% |
| Total Liquid Assets | $31.22 Million | 29.31% |
Asset Resilience Insights
- Very High Liquidity: Electra Therapeutics, Inc. Common stock maintains exceptional liquid asset reserves at 29.31% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Electra Therapeutics, Inc. Common stock Industry Peers by Asset Resilience Ratio
Compare Electra Therapeutics, Inc. Common stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX |
Biotechnology | 4.91% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Seegene Inc
KQ:096530 |
Biotechnology | 24.96% |
Annual Asset Resilience Ratio for Electra Therapeutics, Inc. Common stock (2024–2025)
The table below shows the annual Asset Resilience Ratio data for Electra Therapeutics, Inc. Common stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 53.85% | $53.51 Million | $99.37 Million | +48.71pp |
| 2024-12-31 | 5.14% | $998.00K | $19.42 Million | -- |
About Electra Therapeutics, Inc. Common stock
Electra Therapeutics, Inc. is a clinical-stage biotechnology company. It develops therapies that target signal regulatory proteins for the treatment of novel targets for diseases in immunology and cancer. Its product, ELA026, is a monoclonal antibody that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, enabling medical professio… Read more